Abstract
In this issue of Blood, Hagner et al provide preclinical evidence that CC-122 might be active in both major molecular subtypes of diffuse large B-cell lymphoma (DLBCL).
MeSH terms
-
Animals
-
Antineoplastic Agents / pharmacology*
-
B-Lymphocytes / drug effects*
-
Humans
-
Ikaros Transcription Factor / genetics*
-
Lymphoma, Large B-Cell, Diffuse / drug therapy*
-
Peptide Hydrolases / genetics*
-
Piperidones / pharmacology*
-
Quinazolinones / pharmacology*
-
Signal Transduction / drug effects*
Substances
-
Antineoplastic Agents
-
Piperidones
-
Quinazolinones
-
Ikaros Transcription Factor
-
Peptide Hydrolases